TL;DR
Get oils, diffusers and self-care delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
The FDA has opened a request for information on how early-phase clinical trials of ibogaine drug products should be designed, inviting comments and data on dosing, safety, patient eligibility and oversight. The agency says ibogaine raises scientific questions and serious safety concerns; the request does not approve ibogaine treatment or establish that it is safe or effective. Comments are due November 20, 2026.
The U.S. Food and Drug Administration is seeking public input on how to design early-phase clinical trials of ibogaine drug products, including how to set doses, monitor safety and select participants. The request for information, announced October 5, opens a comment period for data and views that may inform research, but it is not an approval of ibogaine or a finding that the drug is safe or effective.
The FDA is asking for comments on four broad areas: study design and patient populations; dose selection and escalation; safety safeguards; and ethics and independent oversight. The agency is seeking input on specific protocol elements, including eligibility criteria, care settings, stopping rules and safety monitoring.
On dosing, the request describes a possible approach involving small, sequential dose-ascending groups and a starting dose justified by available data and not exceeding 10 milligrams per kilogram. The FDA is seeking input on that approach, rather than announcing it as a final requirement for future trials.
Safety questions include monitoring for cardiac and neurologic adverse events and other protections for participants. The request also asks about informed consent and appropriate independent safety oversight. The FDA says public submissions may help it better understand the potential uses, benefits and risks of ibogaine drug products and inform drug-development approaches.
Trial Design Will Shape Safety Review
The FDA’s request focuses on the rules and protections that could guide the first stages of clinical testing. Decisions about starting doses, dose escalation and monitoring can affect how researchers identify risks before a study expands or moves to later phases. Input from researchers, clinicians, patients and other stakeholders may give the agency additional information as it considers those issues.
The development is relevant to people seeking options for serious conditions, but it does not establish that ibogaine can treat any disorder. The FDA acknowledged that patients may face substantial unmet needs while emphasizing serious safety concerns and the need for rigorous research. Public comments could inform trial design; they do not replace clinical evidence or constitute permission for routine treatment.
ibogaine research safety monitoring devices
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Federal Research Efforts Already Underway
The request is part of federal work connected to President Donald Trump’s April 2026 executive order on accelerating medical treatments for serious mental illness. The FDA described its RFI as its latest action in response to that order, which directed agencies to accelerate psychedelic-medicine research.
In July 2026, the FDA finalized guidance for industry, Psychedelic Drugs: Considerations for Clinical Investigations, offering general considerations for sponsors developing psychedelic drugs. The agency has also allowed an early-phase study of noribogaine hydrochloride, an ibogaine derivative, to proceed under an Investigational New Drug application as a potential treatment for alcohol use disorder. That study is distinct from the new request for public input and does not establish the effectiveness of ibogaine.
The Department of Health and Human Services says its Advanced Research Projects Agency for Health is funding a program to gather safety and efficacy data in early-phase trials, while the National Institute on Drug Abuse is funding research on ibogaine for potential treatment of opioid use disorder. HHS has identified adults with opioid use disorder and adults with PTSD as initial populations for federally supported research, based on available data and the seriousness of those conditions.
“Patients facing serious conditions that have not responded to existing treatments deserve rigorous scientific investigation of promising new approaches.”
— Michael Davis, director of the FDA Center for Drug Evaluation and Research
clinical trial safety monitoring equipment
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
No Trial Rules Finalized Yet
The FDA has not said what changes, if any, it will make after reviewing the submissions. The proposed elements in the request—including the dose-escalation approach and the maximum suggested starting dose—are topics for input, not final trial requirements. It is also unclear how many comments or what kinds of data the agency will receive.
The announcement does not provide results establishing ibogaine’s safety or effectiveness for opioid use disorder, PTSD or other conditions. It does not specify a timeline for an FDA decision on future trial protocols, nor does it describe when the federally supported research programs will report findings. The agency’s mention of cardiac and neurologic risks identifies areas for safeguards; the release does not quantify those risks.
neuroprotective supplements for mental health
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Comments Close November 20
The public has 45 days following publication in the Federal Register to submit comments, data or other information. Submissions can be made electronically through Regulations.gov by searching for Docket No. FDA-2026-N-10429. The FDA also accepts written submissions through its Dockets Management Staff in Rockville, Maryland.
The FDA says the comment period closes Friday, November 20, 2026, and late comments will not be considered. After the period ends, the agency may use the material it receives to inform its approach to ibogaine drug development. The announcement does not give a date for a response or for any resulting trial-design decisions.
cardiac monitoring devices for clinical trials
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
Has the FDA approved ibogaine as a treatment?
No. The FDA announced a request for information about possible early-phase clinical trial designs. The release does not approve ibogaine for treatment or establish that it is safe or effective.
What feedback is the FDA seeking?
The FDA is seeking input on study design and patient populations, dose selection and escalation, safety monitoring and safeguards, and ethics and independent oversight. It also asks about elements such as eligibility criteria, care settings and stopping rules.
What dose approach does the request describe?
The request seeks input on small, sequential dose-ascending groups and a starting dose supported by available data that does not exceed 10 milligrams per kilogram. These are proposed considerations for comment, not final requirements.
When and how can the public submit comments?
Comments are due November 20, 2026. Submit electronically through Regulations.gov by searching for FDA-2026-N-10429, or send a written submission to the FDA Dockets Management Staff at 5630 Fishers Lane, Room 1061, Rockville, Maryland 20852.
Source: primary
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
